Cardiac sarcoidosis is sarcoidosis affecting the heart. Immune-cell clusters and subsequent scarring can disturb heart muscle and electrical activity. Selected definition. Assessment and care address inflammation, rhythm problems and pumping separately. Confidence: high for this diagnostic distinction and the need for specialist assessment; moderate for attributed treatment frameworks. No independent drug, device or supplement benefit estimate is established here.
- Heart block, dangerous ventricular rhythms and heart failure are distinct concerns in cardiac sarcoidosis.
- Symptoms can be absent; unexplained heart findings still need an assessed diagnosis.
- Active inflammation and lasting scar answer different questions and can require different care.
- MRI, PET and rhythm recordings have complementary roles; one result is not a home diagnosis.
- Follow-up remains important after a quieter phase, and steroid changes require the prescriber’s plan.
- Evidence summary
- What cardiac sarcoidosis means
- Inflammation and scar have different consequences
- Specialist treatment addresses several problems
- Supplements, calcium and everyday activity
- Diagnostic certainty and treatment response
- Emergency symptoms and treatment harms
- Medicine combinations, vaccines and stopping treatment
- Multisystem disease and people needing individual assessment
- MRI, PET and follow-up after a quieter phase
- Laboratory mechanisms and evidence limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Definition and cardiac complications | Actual provider/public descriptions and original specialist review | Provider/public routes separate from individual contributors; review names public/foundation support and commercial author ties. | Recognized disease scope; symptoms alone do not establish or exclude it. |
| Imaging and diagnostic certainty | Selected AHA original/summary and clinic explanation | AHA relevant author/reviewer interests disclosed; exact development and supporting-study allocations unclosed. | Complementary assessment roles; no test-performance percentage or diagnostic cutoff. |
| Inflammation and complication care | Attributed expert and provider frameworks | Society/provider finances separately traced; connected expert and original-trial chains not cleared. | Clinical context only; no independent medicine/device efficacy estimate or universal implant rule. |
| Medicine and supplement safety | Selected dated NHS/NCCIH warnings | Public funding plus permitted gifts distinguished from exact page/contributor/trial finance. | Prescriber-led safety assessment; no dose, taper or supplement substitution. |
What cardiac sarcoidosis means
Sarcoidosis can affect multiple organs. The general NHS description includes lungs, lymph nodes, skin and other sites; it does not provide a cardiac severity grade. Dated general context. Do not interpret a reassuring account of mild lung disease as a verdict about the heart.
The Sussex specialist clinic identifies advanced heart block, heart failure and potentially life-threatening rhythm disturbances as important cardiac complications. Some people have no symptoms. Selected cardiac scope. A heart assessment therefore addresses more than whether someone currently feels breathless.
Ask the team to distinguish suspected involvement, a supported cardiac diagnosis and a particular complication. “Sarcoid heart disease” and “cardiac sarcoidosis” are commonly used for this scope; neither tells you which chamber, electrical problem or inflammatory finding has actually been documented. Record the clinician’s explanation rather than assigning yourself a stage from a symptom list.
Inflammation and scar have different consequences
The original 2023 specialist review describes granulomatous inflammation and fibrotic injury, with cardiac disease sometimes presenting before recognized involvement elsewhere. Electrical and heart-failure consequences require attention alongside inflammation. Selected disease framework. This is attributed expert context, not a prediction for a particular patient.
Ask whether a finding represents active inflammation, established scar or another explanation. A treatment intended to suppress inflammatory activity and a device intended to address an electrical risk do not have interchangeable purposes. An improved inflammatory test should be discussed alongside the rhythm and heart-function findings, rather than treated as a complete clearance.
The cause is not fully understood. Dated cause context. This guide does not attribute a person’s disease to ordinary stress, a particular food, mold exposure or a supplement deficiency. Such an explanation would require evidence beyond a biological possibility or the timing of symptoms.
Specialist treatment addresses several problems
The AHA’s own 2024 summary describes corticosteroid-based immunosuppression for clinically significant disease with active inflammation. Attributed treatment role. An inflammatory treatment decision needs the clinician’s assessment of diagnostic confidence, activity, expected purpose and harms; this is not a prescription menu.
Cleveland Clinic separately describes heart-failure and rhythm medicines, pacemakers, implantable cardioverter defibrillators and selected ablation roles. Selected complication-care roles. These are options for different problems, rather than a sequence that everyone should receive. This guide supplies no implant threshold or claim that a particular device eliminates all risk.
Ask which part of the plan treats inflammation, which treats a complication and what observation will guide reassessment. If two services prescribe different treatments, request a shared account of the intended combination. A recommendation is clinical context; it does not certify that the trials underlying every medicine or device were financially independent.
Supplements, calcium and everyday activity
NHS sarcoidosis advice says calcium or vitamin D supplements should be taken only if advised by a doctor. Selected supplement caution. Bone-health support during steroid treatment and sarcoidosis-related calcium concerns need a coordinated decision; this guide gives no replacement dose or universal supplement instruction.
NCCIH advises discussing supplements because adverse effects and interactions can occur. Selected dated safety context. Bring the actual ingredients for herbal products, concentrated vitamins and preparations marketed for immune support. No independently checked supplement is established here as a replacement for cardiac sarcoidosis care.
Ask the specialist what activity, work and travel advice applies to the documented rhythm risk, heart function and current treatment. Do not use a symptom-free day as a self-administered exercise clearance. A useful plan states who can answer activity questions and which change requires earlier contact, without relying on an online challenge or fixed performance target.
Diagnostic certainty and treatment response
The AHA original treats diagnostic certainty as a spectrum and explains the limitations of heart biopsy in patchy disease. A negative biopsy alone does not exclude involvement. Selected diagnostic framework. This article adopts no diagnostic score, tissue-sampling instruction or test-performance percentage.
The diagnostic discussion should identify what supports the conclusion, what alternatives remain and whether another organ’s findings contribute. Ask whether a result changes confidence in the diagnosis, inflammatory activity or risk assessment. Those are related questions, but a positive result for one should not be silently presented as an answer to all three.
When reviewing response, ask what the team compared: symptoms, inflammatory imaging, heart function, rhythm recordings or medicine tolerability. “Better” should refer to a stated outcome and time point. This guide provides no cure claim, survival percentage, fixed recovery deadline or independent ranking of immunosuppressive drugs.
Emergency symptoms and treatment harms
Current NHS arrhythmia advice treats palpitations with chest pain, breathlessness, dizziness or fainting as an emergency. Current urgent instructions. Use the local emergency service; UK instructions use 999. If those symptoms have stopped, the NHS still advises urgent assessment rather than waiting for a routine appointment.
Dated NHS prednisolone advice identifies infection warnings and possible mood, sleep, glucose and bone effects. Selected safety context. Tell the treating service about suspected infection or troubling adverse effects. A feeling of being unwell should not automatically be assigned to sarcoidosis while medicines are affecting immunity.
Ask the prescriber for the actual urgent contact, medicine-warning information and what to do if a planned review cannot take place. This article does not supply side-effect frequencies, reassurance that a symptom is harmless, or a substitute for an emergency assessment. Take the reconciled medicine list to the service assessing a new concern.
Medicine combinations, vaccines and stopping treatment
Dated NHS methotrexate advice asks patients to report pregnancy or breastfeeding, infection, severe kidney or liver problems and a planned live vaccine before treatment. Selected assessment cautions. These are reasons for individualized review, not a complete interaction list or a declaration that all such circumstances receive the same decision.
Dated NHS prednisolone advice warns against stopping without the doctor’s involvement. Selected stopping warning. Do not design a taper from this guide, stop because a scan looks quieter, or restart from an old supply. Request the prescriber’s instructions if a dose cannot be taken or a refill is delayed.
Bring prescriptions, non-prescription medicines, supplement ingredients, allergies and any proposed vaccination to one medicine review. Ask which clinician coordinates changes. The existence of a specialist regimen does not mean a second clinic can infer the dose or monitoring requirements from the condition’s name alone.
Multisystem disease and people needing individual assessment
Sussex describes a multidisciplinary service involving cardiology, respiratory medicine, rheumatology, nuclear medicine and cardiac imaging. Selected care-coordination role. Ask who coordinates the heart plan with findings in other organs and who should receive a new report.
Pregnancy plans, childhood, infection history, kidney or liver disease and an existing implanted device belong in the actual specialist assessment. This guide does not establish blanket pregnancy safety, pediatric eligibility, a universally suitable immunosuppressant or compatibility with a particular scanning procedure.
A referral should explain the unexplained finding rather than merely request a scan. Bring earlier ECGs, rhythm reports, images and the current medicine list if available. Ask whether the specialist is assessing possible sarcoidosis, a known complication or a different diagnosis; those referral questions can lead to different next steps.
MRI, PET and follow-up after a quieter phase
The AHA summary describes MRI for myocardial involvement and PET for inflammatory activity and treatment assessment. Selected complementary imaging roles. Ask the team what the proposed study is intended to resolve and obtain the imaging service’s preparation instructions; this guide gives no fasting or medicine-pause protocol.
The Sussex clinic emphasizes continued follow-up because activity can vary and recur. Selected follow-up rationale. The 2023 review also distinguishes ongoing scar-related consequences from active inflammation. Selected complication distinction. A quieter inflammatory phase should therefore be discussed within the complete heart plan.
Request a written account of the diagnosis, tests to be reviewed, service responsible and warning contact. Ask who receives a rhythm-monitor or scan result and what happens if the appointment is missing. This guide sets no universal surveillance interval or automatic stopping point for specialist care.
Laboratory mechanisms and evidence limits
An immune mechanism can explain why a treatment is researched without establishing benefit in patients. Cell experiments, animal work and changes in an inflammatory marker are different from human symptoms, arrhythmias, hospital admission or survival. No laboratory finding is used here as a supplement or drug efficacy verdict.
The selected AHA statement and specialist review are expert frameworks with disclosed relevant commercial relationships. Clinical recommendations remain attributed. Neither their institutional reputation nor publication in a respected journal clears the financial chain of every underlying study.
This article excludes positive and null manufacturer-funded outcome claims from an independent efficacy conclusion. It gives no mortality reduction, diagnostic accuracy percentage or product ranking. The evidence supports an educational account of disease, investigation roles, specialist care and safety; uncertainty about a specific treatment comparison remains explicit.
Funding and source roles
Research funding at a glance
23 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
A public clinic, a society statement, an author review and a financial report perform different roles. The clinic’s own provider accounts were checked separately; national NHS financing is not assigned to that trust. Individual leaflet payments and outside contributor interests remain incomplete.
AHA author/reviewer financial declarations and the 2023 review’s named support are recorded below. Institutional income routes do not establish a payment for this particular clinical document. Relevant disclosed commercial relationships keep these expert sources in Tier 3, with provisional grade C.
The AHA statement’s August 2024 correction changed a population estimate and ICD wording. The complete indexed correction body was read, though its direct download was blocked. No numerical estimate or device criterion is adopted here. Provisional grades describe source roles and remaining financial gaps, separately from methodological quality.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| National NHS sarcoidosis, October 6, 2022; scheduled review overdue | Separate national current accounts and content policy. Exact page, individual contributor and supporting-study payment chains unclosed. | United Kingdom; national NHS England information, registered Leeds contact. Provider finances are separate. | Tier 2 clinical context, provisional. | C provisional — actual dated body read; scheduled review has passed. Selected warnings remain attributed; current prescriber/local guidance required. Full contributor, page and original-study financial chains unclosed. |
| National NHS arrhythmia, October 28, 2024; emergency context | Separate national current accounts and content policy. Exact page, individual contributor and supporting-study payment chains unclosed. | United Kingdom; national NHS England information, registered Leeds contact. Provider finances are separate. | Tier 2 clinical context, provisional. | B provisional — clinical/public accountability supports accuracy; exact contributors, page payments and underlying-study finances remain incomplete. |
| National NHS prednisolone adverse effects, February 24, 2022; review overdue | Separate national current accounts and content policy. Exact page, individual contributor and supporting-study payment chains unclosed. | United Kingdom; national NHS England information, registered Leeds contact. Provider finances are separate. | Tier 2 clinical context, provisional. | C provisional — actual dated body read; scheduled review has passed. Selected warnings remain attributed; current prescriber/local guidance required. Full contributor, page and original-study financial chains unclosed. |
| National NHS prednisolone stopping advice, February 24, 2022; review overdue | Separate national current accounts and content policy. Exact page, individual contributor and supporting-study payment chains unclosed. | United Kingdom; national NHS England information, registered Leeds contact. Provider finances are separate. | Tier 2 clinical context, provisional. | C provisional — actual dated body read; scheduled review has passed. Selected warnings remain attributed; current prescriber/local guidance required. Full contributor, page and original-study financial chains unclosed. |
| National NHS methotrexate assessment, March 14, 2023; review overdue | Separate national current accounts and content policy. Exact page, individual contributor and supporting-study payment chains unclosed. | United Kingdom; national NHS England information, registered Leeds contact. Provider finances are separate. | Tier 2 clinical context, provisional. | C provisional — actual dated body read; scheduled review has passed. Selected warnings remain attributed; current prescriber/local guidance required. Full contributor, page and original-study financial chains unclosed. |
| NCCIH supplement safety, January 2019; selected safety context only | Separate NCCIH historical public appropriations and Gift Fund authority. Current donor/page allocations and complete contributor/source-study chains unclosed. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 2 public safety context, provisional. | C provisional — actual selected safety original read; public scientific accountability favors accuracy, while dated summaries and unclosed author/study finance limit use. No independent efficacy conclusion. |
| NHS England own 2025–2026 audited accounts | Own 2025–2026 audited accounts identify DHSC grant-in-aid as principal finance, with services, research/training and other consolidated income. Parent and consolidated accounts differ. Exact website-page allocation unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| National NHS website content and funding policy, 2022 | Own 2022 policy says DHSC funds the national website, which rejects advertising/corporate sponsorship and requires staff/outside-agent interest reporting. This does not certify each supporting study or hospital’s finances. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| NCCIH actual appropriation history, through FY 2024 | Own appropriation history documents congressional finance through FY 2024; not a current enacted 2026 amount or page budget. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| NCCIH separate conditional/unconditional Gift Fund authority | Own authority permits conditional and unconditional gifts/bequests in a fund separate from appropriation; operating costs from appropriation. Complete current donor ledger and clinical-page allocation unclosed. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| Sussex cardiac sarcoidosis clinic (2025) | Separate own current provider accounts. Names Alexander Liu and Raj Selvaraju; their complete outside interests and exact page/study allocations unclosed. | United Kingdom; own trust HQ Worthing Hospital, Lyndhurst Road, Worthing, West Sussex. | Tier 2 provider clinical education, provisional. | C provisional — actual November 2025 body read; clinical accountability supports accuracy, while referral/service interests and unresolved contributor/trial finances remain. |
| University Hospitals Sussex own 2025–2026 accounts, full 272-page original | Selected income notes disclose NHS commissioners/public bodies, private/overseas care, research, training, services, grants, donations and investments. Separate research passages identify commercial trials and NIHR. Group charitable consolidation differs from the trust; no clinic payment inferred. | United Kingdom; University Hospitals Sussex, Worthing HQ independently corroborated by own clinical contact. | Tier 3 institutional financial self-report. | B provisional — actual full 272-page report opened; selected income/research passages read. Statutory accountability supports accuracy; complete donor/contributor and page/trial allocations remain unclosed. |
| AHA own cardiac sarcoidosis statement summary, April 18, 2024 | Same expert source chain as original declarations; separate institutional income. Summary contributor Paul St Laurent named; exact summary payment and supporting-study chains unclosed. | United States; AHA Dallas; full individual/backer jurisdictions unclosed. | Tier 3 connected expert statement summary. | C provisional — actual own 2024 summary read; expert review favors accuracy, while relevant primary author/reviewer interests and original-study finance gaps prevent independent efficacy clearance. |
| AHA statement: corrected clinical replica | Declarations in separate early full original; correction checked. Complete development receipts and original-study finance unclosed. | Original US/Canadian affiliations; German replica host is separate. | Tier 3 expert statement with relevant disclosed commercial interests. | C provisional — actual 23-page corrected clinical body read selectively; declaration appendix absent from this replica. Official direct full text blocked. No numerical criteria or outcome estimate adopted. |
| AHA statement: declaration replica | AHA commissioned statement. Author Nisha Gilotra reports Kiniksa advisory/consulting; reviewer Farooq Sheikh Abbott speaking. Separate society income. Full outside payment, company jurisdiction and study chains unclosed. | Original primarily US/Canadian authors; Russian replica host is separate. | Tier 3 disclosed connected expert source, financial context. | C provisional — actual full 20-page early primary replica and financial tables read. Self-disclosure favors transparency but cannot establish complete interests, source payment or trial independence. |
| AHA correction (August 2024) | Originating expert/author chain in separate declarations. Correction-specific finance unclosed. | United States; AHA publisher record for international expert group. | Tier 3 source-context correction record. | C provisional — complete indexed original correction body available; direct download blocked. Correction concerns population estimate, ICD wording and a reference; clinical thresholds excluded. |
| AHA own 2024–2025 annual report, full 36-page original; selected finance | Own annual report describes contributions, events, bequests, training and other revenue. It names BMS, Cytokinetics and Bayer in separate programmes. No particular sarcoidosis statement payment inferred; full donor and study register unclosed. | United States; AHA Dallas national contact separately checked. Complete company ownership/backer jurisdictions unclosed. | Tier 3 institutional financial self-report. | B provisional — actual 36-page own report selected finance/corporate passages read; public scrutiny favors accuracy, while institutional fundraising incentives and incomplete allocation chains remain. |
| AHA own national contact and Dallas jurisdiction | Own Dallas contact; income discussed in separate report. No individual payment established. | United States; Dallas, Texas national center. | Tier 3 institutional contact self-report. | B provisional — actual own contact read; a verifiable address does not establish financial independence. |
| Lehtonen and colleagues, original 2023 cardiac sarcoidosis review with funding/conflicts | Original names Finnish Medical Foundation, government medical-research grant, Aarne Koskelo Foundation and Finnish Foundation for Cardiovascular Research. Mäyränpää reports Boehringer Ingelheim, BMS, MSD, Takeda, Bayer, Amgen, Roche and Aiforia lecture/advisory ties; Uusitalo Pfizer lectures and GE Healthcare collaboration. Full donor, payment and trial chains unclosed. | Finland; Helsinki university/hospital authors. Complete foundation/company HQ, ownership and contributor jurisdictions unclosed. | Tier 3 expert review with relevant disclosed commercial relationships. | C provisional — actual full 2023 original and declarations read; expert scrutiny favors accuracy, while disclosed incentives, dated evidence and unresolved supporting-study finance remain. Not an independent efficacy review. |
| Cleveland Clinic own 2025/2024 audited accounts, March 9, 2026 | Actual 75-page own 2025/2024 consolidated accounts, audited March 9, 2026, disclose patient/payer income, management/advisory services, research grants, gifts/bequests and investments. Selected notes read; no clinical-page allocation or full named donor/trial chain certified. | United States; own clinical footer Cleveland, Ohio; multinational system and complete contributor/backer jurisdictions separately unclosed. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| Cleveland Clinic own advertising policy, January 2020 | Actual January 2020 policy identifies advertising/sponsorship, requires substantiated health claims and prohibits apparent product/advertiser endorsement. Current named advertisers, exact page receipts and individual interests unclosed. | United States; own clinical footer Cleveland, Ohio; multinational system and complete contributor/backer jurisdictions separately unclosed. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| Cleveland Clinic own medical editorial policy | Actual own policy describes expert medical review and editorial checking. This is a governance statement, not a complete author, advertiser or original-trial financial register. | United States; own clinical footer Cleveland, Ohio; multinational system and complete contributor/backer jurisdictions separately unclosed. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| Cleveland Clinic cardiac sarcoidosis, July 22, 2025; selected clinical roles | Separate own accounts, advertising policy and review policy. Named reviewer, exact page and underlying-trial payment chains unclosed. | United States; Cleveland, Ohio provider; complete individual and backer jurisdictions unclosed. | Tier 2 provider clinical education, provisional. | C provisional — actual July 2025 body read; clinical accountability favors accuracy, while service/advertising interests, simplification and unresolved contributor/trial finance remain. No independent outcome clearance. |
Frequently asked questions
Can cardiac sarcoidosis occur without obvious symptoms? Yes; the specialist clinic describes this possibility. Follow the assessed heart plan rather than using symptoms alone as clearance.
Does sarcoidosis elsewhere prove heart involvement? No. Ask what the actual cardiac assessment supports and which alternative explanations were considered.
Do MRI and PET answer the same question? They have complementary roles. Ask what the clinician intends to learn from each study.
Does a negative heart biopsy settle the diagnosis? Patchy involvement limits interpretation; see the diagnostic discussion above.
Can I stop steroids after a quieter scan? Obtain the prescriber’s plan. This guide gives no stopping or tapering regimen.
Can I take vitamin D for steroid-related bone health? Sarcoidosis makes that an individualized clinical discussion; do not start a dose from this article.
Sources and funding notes
Actual Sussex November 2025 clinical body and its own current 272-page 2025–2026 accounts opened; selected income and commercial/public research passages read, without clinic allocation. AHA own 2024 summary, corrected 23-page clinical replica and early full 20-page primary replica financial tables read. The early replica is used for declarations only. Complete August 2024 indexed primary correction body read; direct original download blocked. Population and ICD amendments not reproduced as numerical criteria. Own AHA 2024–2025 income/corporate report and Dallas contact separately checked. Full 2023 Lehtonen original and named funding/conflicts read. Current Cleveland clinical body and separate own audited/policy originals checked. NHS general sarcoidosis, prednisolone and methotrexate pages have overdue scheduled reviews; selected safety context remains dated. Current arrhythmia emergencies, national accounts/policy and separate NCCIH budget/gift originals checked. Full contributor, company/foundation jurisdiction, individual page and original-study financial chains remain incomplete. Consolidated summaries keep conservative aggregate source-derived budgets below 200 words per original, including both AHA replicas as the same paper. No personal dose, test cutoff, scan preparation, medicine pause, surveillance interval, device eligibility threshold, recovery promise or independent corporate outcome claim.
- National NHS sarcoidosis, October 6, 2022; scheduled review overdue — Selected dated general scope, cause uncertainty and supplement caution only
- National NHS arrhythmia, October 28, 2024; emergency context — Selected current urgent warning instructions, not sarcoidosis diagnosis
- National NHS prednisolone adverse effects, February 24, 2022; review overdue — Selected dated medicine harms; no frequencies or reassurance
- National NHS prednisolone stopping advice, February 24, 2022; review overdue — Selected dated stopping warning only; no dose or taper
- National NHS methotrexate assessment, March 14, 2023; review overdue — Selected dated assessment cautions; not cardiac efficacy or a personal regimen
- NCCIH supplement safety, January 2019; selected safety context only — Selected dated supplement safety, not sarcoidosis benefit
- NHS England own 2025–2026 audited accounts — Separate current national institutional finance, not Sussex provider allocation
- National NHS website content and funding policy, 2022 — Separate national editorial/governance context
- NCCIH actual appropriation history, through FY 2024 — Separate historical budget record, not current source-page payment
- NCCIH separate conditional/unconditional Gift Fund authority — Separate permitted gift route, not a verified donor receipt
- Sussex cardiac sarcoidosis clinic (2025) — Selected cardiac scope, multidisciplinary and follow-up roles only; no claimed prevention rate
- University Hospitals Sussex own 2025–2026 accounts, full 272-page original — Own current provider income and research routes only; no disease-page allocation
- AHA own cardiac sarcoidosis statement summary, April 18, 2024 — Selected attributed inflammatory-treatment and complementary imaging roles only
- AHA statement: corrected clinical replica — Selected diagnostic context; corrected replica.
- AHA statement: declaration replica — Early-version declarations only; clinical criteria excluded.
- AHA correction (August 2024) — Correction context only; numerical criteria excluded.
- AHA own 2024–2025 annual report, full 36-page original; selected finance — Own 2024–2025 income/corporate route only; no sarcoidosis document attribution
- AHA own national contact and Dallas jurisdiction — Actual institutional jurisdiction only; no contributor or trial clearance
- Lehtonen and colleagues, original 2023 cardiac sarcoidosis review with funding/conflicts — Selected disease and complication framework only; no cohort outcomes or product efficacy
- Cleveland Clinic own 2025/2024 audited accounts, March 9, 2026 — Separate own current audited institutional finance, not clinical-page payments
- Cleveland Clinic own advertising policy, January 2020 — Separate advertising/sponsorship policy, not exact named receipts
- Cleveland Clinic own medical editorial policy — Separate medical-review governance, not full individual financial clearance
- Cleveland Clinic cardiac sarcoidosis, July 22, 2025; selected clinical roles — Selected definition and complication-care roles only; triggers, survival figures and cure/prevention claims excluded
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.